EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Subcutaneous EPKINLY™ is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory large B-cell lymphoma after two or more lines...

Related Keywords

Japan ,United States ,Tokyo ,New Jersey ,Denmark ,Netherlands ,Copenhagen ,Køavn ,Japanese ,Koji Izutsu ,Abbvie Biotechnology Ltd ,Exchange Commission ,Genmab Us Inc ,Japanese Society Of Hematology ,Japan Ministry Of Health ,Twitter ,National Cancer Center Hospital ,Head Of The Hematology Department ,Japan Ministry ,Hematology Department ,National Cancer Center ,Chief Executive Officer ,Largeb Cell Lymphoma ,Follicular Lymphoma ,Release Syndrome ,Full Prescribing Information ,Medication Guide ,Media Release ,Annual Report ,Y Shaped Genmab ,Abbvie Biotechnology ,Patient Survey ,Japanese Journal ,Clinical Oncology ,Practical Guidelines ,Hematological Malignancies ,Japanese Society ,British Journal ,Markets ,